Stock Screener App

Gratuito -

Installare

2.7906

2.21% 0.0706

Ovid Therapeutics Inc (OVID)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Ovid Therapeutics Inc Borsa (OVID) Ultime notizie

Ovid Therapeutics Inc.(NasdaqCM:OVID) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2500 Growth Benchmark - marketscreener.com

Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Index - marketscreener.com

Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Value Benchmark - marketscreener.com

Ovid Therapeutics Inc.(NasdaqCM:OVID) added to Russell Microcap Value Benchmark Index - marketscreener.com

Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Growth Benchmark - marketscreener.com

Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell Microcap Index - marketscreener.com

Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 3000E Growth Benchmark - marketscreener.com

Ovid Therapeutics Inc (OVID) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Ovid Therapeutics Inc. Actuals & Estimates (NASDAQ:OVID) - TradingView

OVID Forecast — Price Target — Prediction for 2027 - TradingView

AQST Stock Price and Chart — NASDAQ:AQST - TradingView

1OT Forecast — Price Target — Prediction for 2027 - TradingView

Ovid Therapeutics Inc. Actuals & Estimates (SWB:1OT) - TradingView

Price to earnings forward of Ovid Therapeutics Inc. – NASDAQ:OVID - TradingView

Price to sales forward of Ovid Therapeutics Inc. – NASDAQ:OVID - TradingView

Ovid Therapeutics Inc (OVID) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy - Sahm

Ovid Therapeutics Inc.(NasdaqCM: OVID) added to S&P Biotechnology Select Industry Index - marketscreener.com

OVIDOvid Therapeutics Inc Latest SEC Filings - Finviz

Ovid Therapeutics (NASDAQ: OVID) grants director Anna Greka 130,000 stock options - Stock Titan

Ovid Therapeutics (OVID) director files initial Form 3 - Stock Titan

Ovid Therapeutics Inc (OVID) Valuation: PE, PB & Fair Value Analysis - TradingKey

Ovid Therapeutics Inc (OVID) Institutional Confidence - TradingKey

Ovid Therapeutics Inc (OVID) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Ovid Therapeutics Inc (OVID) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Ovid Therapeutics Inc (OVID) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Ovid Therapeutics Inc (OVID) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Ovid Therapeutics Inc (OVID) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

OVID: Multiple clinical milestones and strong financial runway position the pipeline for significant value creation - TradingView

Ovid Therapeutics Shareholders Back Board and Governance Proposals - The Globe and Mail

Ovid Therapeutics (OVID) Slips 1.97% as Shares Test Key Support LevelsStrong Buy Stocks - newsline.com

Ovid Therapeutics (NASDAQ: OVID) shareholders approve director, pay and auditor - Stock Titan

Ovid Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus

Ovid Board Move Puts Scientific Strategy Back In Focus - Kalkine Media

Ovid Therapeutics Expands Board, Appoints New Scientific Director - The Globe and Mail

Ovid Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

Ovid Therapeutics appoints Anna Greka to board of directors - Investing.com UK

Ovid Therapeutics appoints Anna Greka to board of directors By Investing.com - Investing.com Canada

Anna Greka joins Ovid Therapeutics (NASDAQ: OVID) board, expanding it to seven - Stock Titan

Ovid Therapeutics Appoints Leading Physician-Scientist and - GlobeNewswire

Ovid Therapeutics (OVID) Edges Higher: Key Levels in FocusVolume Climax - dars.gov.et

Ovid Therapeutics (OVID) Gains Nearly 4% as Shares Test Key ResistanceUnusual Put Volume - newsline.com

Will Ovid’s golden age of KCC2 metamorph CNS? - BioWorld News

H.C. Wainwright Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $4 - Moomoo

OVID SEC FilingsOvid Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Point72 (OVID) discloses shared 1.3% position, including warrants - Stock Titan

Eventide (OVID) discloses 12.8M-share, 7.3% position in Ovid Therapeutics - Stock Titan

Ovid Therapeutics (OVID) Schedule 13G: Sirenia/manager report 9.9% stake - Stock Titan

Balyasny group holds 5.33% of Ovid (NASDAQ: OVID) across funds - Stock Titan

Former Ovid CEO Dr. Jeremy Levin’s rallying cry for biotech - Pharma Voice

[SCHEDULE 13G/A] Ovid Therapeutics Inc. Amended Passive Investment Disclosure - Stock Titan

Jeremy Levin reports 4.5% stake in Ovid Therapeutics (NASDAQ: OVID) - Stock Titan

We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely - Yahoo Finance

Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $7 - Moomoo

LifeSci Capital Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5 - Moomoo

B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com - Investing.com Australia

B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target - Investing.com India

BNTX

$94.70

0.33%

RPRX

$56.85

1.64%

ROIV

$35.04

2.35%

MRNA

$71.81

4.73%

ONC

$285.00

1.93%

ALNY

$300.08

1.09%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters